Transaction is Hopewell’s first commercial license of proprietary lipid nanoparticles (LNPs) Hopewell’s LNPs are the preferred delivery solution for the cancer vaccine technology that Foxcroft licensed from Tufts University in 2025 Foxcroft will conduct its first large mammal (canine) trial in mid-2026, using Hopewell’s LNPs WOBURN, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Hopewell Therapeutics, Inc. , a Boston-based next-generation lipid nanoparticle (LNP) company (“ Hopewell ”), today...

Armstrong Asia   of Singapore selected as NeuroSigma’s manufacturing partner Investment led by Checkmate Capital  as part of strategic partnership with Armstrong Asia First commercial units to be delivered in March 2026    LOS ANGELES, Dec. 15, 2025 (GLOBE NEWSWIRE) --   NeuroSigma, Inc. , a Los Angeles-based bioelectronics company, today announced completion of an approximately $1 million investment into a high-volume manufacturing line for the second-generation Monarch external Trigeminal...

Company dispensed over 1,000 FDA-cleared systems in pilot phase; unveils new website and second-generation device for early 2026 launch LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. , a Los Angeles-based bioelectronics company, today announced the successful completion of its pilot commercialization program for the first-generation Monarch eTNS ®  System and the launch of a new website in preparation for release of its second-generation Monarch device. The pilot program...